OncoCyte has a strong R&D product pipeline focused on the greatest unmet need in the areas of Lung, Breast, and Bladder cancer screening.
The Company’s initial focus will be on confirmatory diagnostics in areas of high unmet need refining the diagnoses associated with:
- Low Dose CT indeterminate findings for lung cancer
- Mammogram BIRADS 3-4 (suspicious findings) for breast cancer
- Cytology indeterminate findings for bladder cancer